1108154-60-4

Upstream product

• 34737-89-8 1-Benzyl-3-methyl-4-piperidon 
• 181269-69-2 tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1108154-56-8 tert-butyl 4-(4-chlorophenyl)-3-methyl-5,6-dihydropyridine-1(2H)-carboxylate 

Downstream Products

• 1108154-61-5 (3S,4S)-4-(4-chlorophenyl)-3-methylpiperidine-3,4-diol hydrochloride 
• 1352621-89-6 tert-butyl (R)-1-((3S,4S)-4-(4-chlorophenyl)-3,4-dihydroxy-3-methylpiperidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate 
• 1352621-92-1 (3S,4S)-4-(4-chlorophenyl)-3-methyl-1-D-valyl-3,4-piperidinediol 
• 1352621-98-7 (R)-N-((R)-1-((3S,4S)-4-(4-chlorophenyl)-3,4-dihydroxy-3-methylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3,3-difluorocyclopentanecarboxamide 

Relevant academic research and scientific papers

PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune

PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes modulators of MIP-1α of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R1, R3, R4, R5, R5a and R5b, are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators of formula (I) are disclosed.